Complications of androgen-deprivation therapy in prostate cancer: The other side of the coin

BJU International

Volumn 103, Issue 8, 2009, Pages 1020-1023

  Hoffmann, Paul ^a   Schulman, Claude ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; GONADORELIN DERIVATIVE; PLACEBO;

ANDROGEN DEPRIVATION THERAPY; BODY MASS; BONE DENSITY; CANCER GROWTH; CANCER LOCALIZATION; CANCER STAGING; CANCER SURVIVAL; CASTRATION; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; CONSERVATIVE TREATMENT; CONTROLLED CLINICAL TRIAL; DEPRESSION; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DRUG FATALITY; ERECTILE DYSFUNCTION; EXTERNAL BEAM RADIOTHERAPY; FAT MASS; FATIGUE; FOLLOW UP; GYNECOMASTIA; HEART INFARCTION; HOT FLUSH; HUMAN; HYPOGONADISM; ISCHEMIC HEART DISEASE; LIBIDO DISORDER; MEDICAL RESEARCH; METABOLIC SYNDROME X; MONOTHERAPY; MORBIDITY; MUSCLE ATROPHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; ORCHIECTOMY; PATIENT SELECTION; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SIDE EFFECT; TREATMENT DURATION; TREATMENT FAILURE;

ADULT; AGED; ANDROGEN ANTAGONISTS; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; HUMANS; HYPOGONADISM; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS;

EID: 63449094686     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.08293.x     Document Type: Note

References (20)

1. Kirk D. Timing and choice of androgen ablation. Prostate Cancer Prostatic Dis 2004 7 : 217 22
2. Studer UE, Hauri D, Hanselmann S et al. Immediate versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment: results of the randomized trial SAKK 08/88. J Clin Oncol 2004 22 : 4109 18
3. Studer UE, Whelan P, Albrecht W et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent. European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol 2006 24 : 1868 76
4. Lu-Yao GL, Albertsen PC, Moore DF et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 2008 300 : 173 81
5. Iversen P, Johansson JE, Lodding P et al. Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6. J Urol 2004 172 : 1871 6
6. Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999 353 : 878 82
7. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005 352 : 154 64
8. Lakka HM, Laaksonen DE, Lakka TA et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002 288 : 2709 16
9. Braga-Basaria M, Dobs AS, Muller DC et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 2006 24 : 3979 83
10. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006 24 : 4448 56
11. Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007 110 : 1493 500
12. D'Amico AV, Denham JW, Crook J et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 2007 25 : 2420 5
13. Efstathiou JA, Bae K, Shipley WU et al. Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. Eur Urol 2008 54 : 816 23
14. Stellato RK, Feldman HA, Hamdy O, Horton ES, McKinlay JB. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. Diabetes Care 2000 23 : 490 4
15. Rodriguez A, Muller DC, Metter EJ et al. Aging, androgens, and the metabolic syndrome in a longitudinal study of aging. J Clin Endocrinol Metab 2007 92 : 3568 72
16. Khaw KT, Dowsett M, Folkerd E et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation 2007 116 : 2694 701
17. Studer UE, Collette L, Whelan P et al. Using PSA to guide timing of androgen deprivation in patients with T0-4, N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol 2008 53 : 941 9
18. Schroder FH. Progress in understanding androgen-independent prostate cancer (AIPC): a review of potential endocrine-mediated mechanisms. Eur Urol 2008 53 : 1129 37
19. Boccon-Gibod L, Hammerer P, Madersbacher S, Mottet N, Prayer-Galetti T, Tunn U. The role of intermittent androgen deprivation in prostate cancer. BJU Int 2007 100 : 738 43
20. Weight CJ, Klein EA, Jones JS. Androgen deprivation falls as orchiectomy rates rise after changes in reimbursement in the U.S. Medicare population. Cancer 2008 112 : 2195 201